↓ Skip to main content

Oncotarget

Article Metrics

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Overview of attention for article published in Oncotarget, July 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
2 news outlets
twitter
30 tweeters
patent
2 patents

Citations

dimensions_citation
243 Dimensions

Readers on

mendeley
209 Mendeley
Title
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Published in
Oncotarget, July 2016
DOI 10.18632/oncotarget.10547
Pubmed ID
Authors

Julie N. Graff, Joshi J. Alumkal, Charles G. Drake, George V. Thomas, William L. Redmond, Mohammad Farhad, Jeremy P. Cetnar, Frederick S. Ey, Raymond C. Bergan, Rachel Slottke, Tomasz M. Beer

Abstract

While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration resistant prostate cancer (mCRPC) showed no evidence of activity. Here we report unexpected antitumor activity seen in mCRPC patients treated with the anti-PD-1 antibody pembrolizumab. Patients with evidence of progression on enzalutamide were treated with pembrolizumab 200 mg IV every 3 weeks for 4 doses; pembrolizumab was added to standard dose enzalutamide. Three of the first ten patients enrolled in this ongoing phase II trial experienced rapid prostate specific antigen (PSA) reductions to ≤ 0.2 ng/ml. Two of these three patients had measurable disease upon study entry; both achieved a partial response. There were three patients with significant immune-related adverse events. One had grade 2 myositis, one had grade 3 hypothyroidism, and one had grade 2 hypothyroidism. None of these patients had a response. Two of the three responders had a baseline tumor biopsy. Immunohistochemistry from those biopsies showed the presence of CD3+, CD8+, and CD163+ leukocyte infiltrates and PD-L1 expression. Genetic analysis of the two responders revealed markers of microsatellite instability in one. The surprising and robust responses seen in this study should lead to re-examination of PD-1 inhibition in prostate cancer.

Twitter Demographics

The data shown below were collected from the profiles of 30 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 209 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Sweden 1 <1%
Unknown 208 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 52 25%
Student > Ph. D. Student 29 14%
Other 21 10%
Student > Bachelor 17 8%
Student > Doctoral Student 13 6%
Other 38 18%
Unknown 39 19%
Readers by discipline Count As %
Medicine and Dentistry 79 38%
Biochemistry, Genetics and Molecular Biology 24 11%
Agricultural and Biological Sciences 21 10%
Immunology and Microbiology 9 4%
Pharmacology, Toxicology and Pharmaceutical Science 6 3%
Other 20 10%
Unknown 50 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2020.
All research outputs
#690,437
of 17,719,454 outputs
Outputs from Oncotarget
#276
of 13,529 outputs
Outputs of similar age
#15,549
of 266,223 outputs
Outputs of similar age from Oncotarget
#13
of 1,106 outputs
Altmetric has tracked 17,719,454 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,529 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,223 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 1,106 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.